EVOLUTION AT MERCK - INVENTING FOR LIFE

MERCK INVENTING FOR LIFE Ebola Others EXTENSIVE VACCINES PIPELINE TARGETING DISEASES WITH SIGNIFICANT UNMET NEED HPV PCV RSV CMV Dengue V114 Adults & Peds GARDASIL V116 Other PCVs MK-1654 V172 (Moderna) V160 V181 V920 Instituto Butantan Dr. Roy Baynes Supporting global appeals to eliminate cervical cancer by improving access to GARDASIL • Increasing gender-neutral vaccination • • Need for prevention of residual disease 13 Phase 3 trials across adults and pediatrics for V114 • Major unmet medical need in infants and elderly • Leading non- genetic cause of neurologic disability • Identified by . CDC / FDA and others as area of critical need • • Major cause of hemorrhagic fever and death ⚫ Partnership with Instituto Butantan allows early access to Phase 3 study results • ⚫ Licensing application under review at FDA, EMA, WHO and African countries • Addressing key areas of unmet need with broad early vaccine pipeline HPV=Human papillomavirus; PCV=Pneumococcal conjugate vaccine; CMV-Cytomegalovirus; RSV=Respiratory syncytial virus | 62 62

View entire presentation